Barclays raised the firm’s price target on Insulet to $220 from $200 and keeps an Equal Weight rating on the shares. The firm cites higher sales projections and rolling forward the price target one year for the increase post the earnings print.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD: